Democrats say Trump increased investments in drugmakers that were given Medicare exemptions

Congressional Democrats have revealed that President Donald Trump's pharmaceutical stock holdings increased significantly after he returned to the White House, with the value growing from $1.7 million in 2024 to as much as $56.2 million by the end of 2025. This growth was largely due to investments in companies that benefited from a Republican-backed law that exempts certain medications from Medicare price negotiations.

The Joint Economic Committee's minority arm released the report, which also highlighted that Trump's portfolio made purchases of up to $2.55 million in shares of pharmaceutical companies with these exemptions on multiple occasions before the legislation was signed in July 2025. Critics argue that this policy could lead to higher costs for Medicare beneficiaries, while the White House denies any ethical concerns, attributing Trump's financial success to business interests that have benefited from his administration's policies.

Brief written by urgent.news from PBS NewsHour's own syndicated text. Machine-written — may contain errors; check the original before relying on it.